Stromedix, a Cambridge, MA-based developer of treatments for a cause of organ failure known as fibrosis, has raised $2 million of a prosposed $15.5 million round of debt financing, according to an SEC filing. The company, founded in 2007, has previously raised $29.4 million from investors including Atlas Venture, Bessemer Venture Partners, Red Abbey Venture Partners, New Leaf Venture Partners, and Frazier Healthcare Ventures. The company’s CEO, Michael Gilman, said in an e-mail that he was not able to be interviewed about the new financing today.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
